AGIO Agios Pharmaceuticals Inc

Price (delayed)

$47.14

Market cap

$2.78B

P/E Ratio

2.08

Dividend/share

N/A

EPS

$22.7

Enterprise value

$1.91B

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In ...

Highlights
The quick ratio has soared by 121% year-on-year and by 15% since the previous quarter
The debt has dropped by 72% year-on-year
Agios Pharmaceuticals's equity has decreased by 25% QoQ

Key stats

What are the main financial stats of AGIO
Market
Shares outstanding
58.95M
Market cap
$2.78B
Enterprise value
$1.91B
Valuations
Price to earnings (P/E)
2.08
Price to book (P/B)
1.91
Price to sales (P/S)
41.86
EV/EBIT
1.2
EV/EBITDA
1.19
EV/Sales
24.28
Earnings
Revenue
$78.75M
EBIT
$1.59B
EBITDA
$1.61B
Free cash flow
-$363.13M
Per share
EPS
$22.7
Free cash flow per share
-$5.19
Book value per share
$24.62
Revenue per share
$1.13
TBVPS
$26.8
Balance sheet
Total assets
$1.87B
Total liabilities
$152.79M
Debt
$101.91M
Equity
$1.72B
Working capital
$1.64B
Liquidity
Debt to equity
0.06
Current ratio
28.07
Quick ratio
27.72
Net debt/EBITDA
-0.54
Margins
EBITDA margin
2,045.4%
Gross margin
98%
Net margin
2,020.9%
Operating margin
-463.7%
Efficiency
Return on assets
103.9%
Return on equity
130%
Return on invested capital
187.8%
Return on capital employed
87.7%
Return on sales
2,021%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
2.93%
1 week
4.34%
1 month
5.58%
1 year
21.9%
YTD
8.79%
QTD
-14.46%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$78.75M
Gross profit
$77.15M
Operating income
-$365.2M
Net income
$1.59B
Gross margin
98%
Net margin
2,020.9%
The revenue has grown by 28% year-on-year
Agios Pharmaceuticals's gross profit has increased by 27% YoY
The operating margin has increased by 26% year-on-year but it has declined by 2.2% since the previous quarter
Agios Pharmaceuticals's operating income has increased by 5% YoY but it has decreased by 2.2% from the previous quarter

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
P/E
2.08
P/B
1.91
P/S
41.86
EV/EBIT
1.2
EV/EBITDA
1.19
EV/Sales
24.28
The P/B is 64% below the 5-year quarterly average of 5.3 and 53% below the last 4 quarters average of 4.1
Agios Pharmaceuticals's equity has decreased by 25% QoQ
The revenue has grown by 28% year-on-year
AGIO's P/S is 17% above its last 4 quarters average of 35.9 but 4.9% below its 5-year quarterly average of 44.0

Efficiency

How efficient is Agios Pharmaceuticals business performance
AGIO's return on equity is down by 24% since the previous quarter
The ROA has contracted by 14% from the previous quarter

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The quick ratio has soared by 121% year-on-year and by 15% since the previous quarter
AGIO's current ratio has surged by 113% year-on-year and by 15% since the previous quarter
The debt is 94% smaller than the equity
The debt to equity has shrunk by 91% YoY but it has increased by 20% QoQ
The debt has dropped by 72% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.